An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

Just hours after GRAP-3 restrictions were implemented, authorities tightened pollution controls in Delhi and surrounding areas on Saturday evening by moving to GRAP-4.

Earlier in the afternoon, the Commission for Air Quality Management (CAQM)—the central agency responsible for monitoring and managing pollution in Delhi and neighbouring states—had imposed GRAP-3 curbs as the Air Quality Index (AQI) surpassed 400, entering the ‘Severe’ category.

By evening, the CAQM reported that the AQI, which was 431 at 4 pm, continued to rise and reached 441 by 6 pm. Under the GRAP system, air quality is divided into four levels: Poor (AQI 201–300), Very Poor (AQI 301–400), Severe (AQI 401–450), and Severe Plus (AQI above 450).

The CAQM stated, “Considering the current air quality trend and to prevent further deterioration in the region, the Sub-Committee on GRAP has decided to implement all measures under Stage IV of the existing GRAP – ‘Severe+’ Air Quality (Delhi AQI > 450) – with immediate effect across the entire NCR. These measures are in addition to the actions already in place under Stages I, II, and III.”

The commission added that the primary reason for the worsening AQI was the weak Western Disturbance moving toward north-west India, rather than local emissions.

GRAP 4 In Delhi: Schools Shift to Hybrid Classes

While schools in Delhi remain open, classes for several grades have moved to a hybrid format, combining both in-person and online learning. The Delhi Directorate of Education (DDE) issued a circular directing all government, aided, and private schools under DOE, NDMC, MCD, and Delhi Cantonment Board to adopt hybrid classes for students up to Class IX and XI wherever online teaching is feasible.

The circular, dated December 13, states: “All Heads of Schools…are directed to conduct classes in schools for children up to Class IX and XI in a ‘Hybrid Mode’ i.e., both physical and online mode (wherever online mode is feasible) with immediate effect until further orders.”

GRAP 4 In Delhi: Are Delhi Schools Open Today?

Yes, all schools under the Delhi Directorate of Education remain open. Students up to Class IX and Class XI can attend classes either physically or online, depending on what they or their parents choose. The hybrid arrangement will continue until further notice. The directive also applies to schools managed by NDMC, MCD, and Delhi Cantonment Board. School authorities have been asked to promptly inform parents and guardians about the arrangements.

GRAP 4 Activated as Pollution Worsens

The move comes after the Commission for Air Quality Management (CAQM) declared Stage 4 of GRAP with immediate effect, as Delhi’s Air Quality Index (AQI) surged into the ‘severe’ category. At 6 am on Sunday, the AQI in the city stood at 462, according to the Central Pollution Control Board’s Sameer app.

GRAP 4 In Delhi: Restrictions Under Stage 4

Stage 4 maintains all measures from Stage 3 and introduces stricter curbs to limit pollution. Among the new restrictions is a total ban on truck traffic entering Delhi, except for vehicles carrying essential goods or providing critical services. Trucks powered by LNG, CNG, electricity, and BS-VI diesel are exempt from the ban.

A widely sold nasal spray is being pulled from shelves across the United States after tests revealed mold and microbial contamination, prompting officials to urge consumers to stop using it right away.

MediNatura New Mexico issued a voluntary recall of ReBoost Nasal Spray on Wednesday, the US Food and Drug Administration said in a public notice. The action follows findings that one specific lot of the product contained yeast and mold, along with unsafe levels of microbial contamination.

Laboratory testing also identified the presence of Achromobacter, a type of bacteria that can cause infections, particularly in people with weakened immune systems. The FDA has advised customers to immediately discontinue use of the affected nasal spray.

Nasal Spray Recall: FDA Flags Microbial and Mold Contamination

MediNatura New Mexico Inc. has voluntarily recalled its ReBoost Nasal Spray after the product was found to contain yeast, mold, and microbial contamination. One of the organisms identified was the bacteria Achromobacter, detected at levels higher than safety limits, according to the US Food and Drug Administration.

The FDA warned that use of the spray could result in severe health effects, particularly for people with weakened immune systems. The agency noted a real risk of serious and potentially life-threatening infections in this group.

Nasal Spray Recall: Possible Symptoms to Watch For

The Hawaii State Department of Health, which also issued a recall notice, listed symptoms that may be linked to the contaminated spray. These include fever, sinus swelling, headaches, facial pain or pressure, and numbness in the face.

Consumers who notice any of these symptoms after using the product have been advised to contact a doctor or healthcare provider.

Nasal Spray Recall: No Adverse Events Reported So Far

As of December 10, MediNatura said it had not received any reports of health problems related to the recalled nasal spray. This information was confirmed by both the FDA and the Hawaii health department.

As per NBC, the nasal spray company was contacted for comment but did not receive a response by the time of publication.

Nasal Spray Recall: About the Product

ReBoost Nasal Spray is a homeopathic product that contains echinacea and other natural ingredients. The company markets it as a remedy for nasal congestion and related symptoms.

Nasal Spray Recall: Which Lots Are Affected

The recall applies to sprays packaged in a white and yellow box containing a 20 mL bottle. The affected lot number is 224268, with an expiration date of December 2027. The product carries NDC number 62795-4005-9 and UPC 787647101863.

What Consumers Should Do

The FDA has urged customers to stop using the nasal spray right away. Those who bought it directly from MediNatura can request a refund by emailing recall@medinatura.com. Consumers who purchased it through other retailers should return it to the place of purchase.

The product was sold both online and in physical stores across the United States.

Danish drugmaker Novo Nordisk has officially introduced its widely known diabetes medication Ozempic in India, pricing the starter dose of 0.25 mg at ₹2,200 per week. According to a Reuters report, the injectable medicine will be available in three strengths in the country: 0.25 mg, 0.5 mg and 1 mg.

Ozempic is a once-weekly injectable prescribed for people living with type 2 diabetes.

Ozempic Price In India

The weekly injection received approval from the US Food and Drug Administration in 2017 for treating type 2 diabetes. Since then, it has grown into a global blockbuster and is also commonly prescribed off-label for weight loss because of its appetite-suppressing effects.

The lowest strength will cost ₹2,200 per week. Prices for the higher doses have also been announced, as per the Reuters report.

Here are the details:

• 1 mg dose: ₹11,175/month
• 0.5 mg dose: ₹10,170/month
• 0.25 mg dose: ₹8,800/month

All you need To know About Ozempic

India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), approved Ozempic, also known as semaglutide, in October this year for adults with type 2 diabetes.

As per the US FDA, Ozempic is prescribed along with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. It is also indicated to reduce the risk of major cardiovascular events in adults with type 2 diabetes who already have heart disease.

As per NDTV Profit, currently, Wegovy is priced at Rs 2,712 per week for the 0.25 mg dose, while the 0.5 mg dose costs Rs 3,462 weekly. The 1 mg dose is also priced at Rs 3,462 per week, and the 1.7 mg dose is available at Rs 4,100 per week. Mounjaro (tirzepatide), a combination therapy of GLP-1 receptor agonist and GIP that helps improve blood sugar control in adults with type 2 diabetes when paired with a healthy diet and regular exercise, is priced at Rs 13,500 per month for the 2.5 mg dose.

How Does Ozempic Help In Weight Loss?

Ozempic mimics the action of a naturally occurring hormone called GLP-1. Here’s how it supports weight loss, as outlined in an earlier HT report.

• It boosts insulin release when blood sugar levels increase.
• It slows down the emptying of food from the stomach, helping people feel full for longer after meals.
• At higher doses, it can also curb appetite, which may aid weight management efforts.

Possible Side-Effects Of Ozempic

As previously reported by Mayo Clinic, some potential side-effects of Ozempic include:

• An increased risk of inflammation of the pancreas.
• Possible gallbladder-related problems.
• According to the FDA, the most commonly reported side effects, seen in at least 5 per cent of patients taking Ozempic, include nausea, vomiting, diarrhoea, abdominal pain and constipation.

This article is intended for informational purposes only and should not be taken as a replacement for professional medical advice.